case_images: PMC11306061_01
case_images: 4D ultrasound of genital development at 24 weeks in the spironolactone-exposed pregnancy. The ultrasound shows no obvious abnormalities in the fetus.
case_images: fphar-15-1404251-g001.jpg
case_images: PMC11306061_01_fphar-15-1404251-g001.jpg
case_images: F1
case_images: Subsequent obstetric examination and fetal ultrasound assessment revealed normal development of the fetal genitalia (Figure 1).
case_images: The entire treatment and monitoring process from spironolactone exposure to postnatal follow-up in the spironolactone-exposed pregnancy. Following spironolactone exposure, the prenatal testing plan includes hepatitis screening (week 16), Down's syndrome screening (week 17), and non-invasive DNA testing with a biochemical exam (week 21). Routine blood tests and biochemical assessments are planned for weeks 24 and 33. A thorough evaluation at week 38 includes routine blood tests, biochemical analysis, coagulation checks, blood grouping, irregular antibody screening, and preoperative immunization.
case_images: fphar-15-1404251-g002.jpg
case_images: PMC11306061_01_fphar-15-1404251-g002.jpg
case_images: F2
case_images: Table 1. The entire treatment and monitoring process from spironolactone exposure to postnatal follow-up in the spironolactone-exposed pregnancy is outlined in Figure 2.